Transposagen Biopharmaceuticals is a privately held biotechnology company with market-leading genetic engineering technology, a large patent portfolio, and a world class team of scientists. We are dedicated to leveraging our technology to provide unique research reagents for drug discovery and other biotechnology uses. We are actively licensing our intellectual property to both academic and industry researchers. In addition, we offer products such as custom animal models, custom cell lines and a variety of genetic engineering tools. We are also in early-stage development of several promising human therapeutics.
Transposagen creates high-value research reagents for sale to academic and industry researchers. Transposagen is able to reach its three primary markets (animal models, cell lines, and research reagents) in a cost-effective manner by performing most high-margin work in house (e.g. genetic engineering and custom reagent creation), and outsourcing lower margin services (e.g. rodent breeding, colony maintenance).
We have established marketing and distribution partners in the United States, Europe and Asia. Our distribution partners include Charles River Laboratories, TransGenic, Inc., Gentaur, Cambridge Biosciences, BioCat, Biolynx, APRO, Funakoshi, and ISTI Bio.
In 2012, Transposagen experienced an over 200% increase in its custom rodent generation business. The reagents business continues to enjoy monthly double digit sales growth, and we are continuing to introduce new products into our target markets. Transposagen is currently developing and testing candidate analogs of TGEN001, an improved human therapeutic in the treatment of pain and has additional therapeutics in the areas of human gene therapy and regenerative medicine.
We are active grant writers for NIH and other research grants. We have averaged $1.5M/year in the most recent 3 year period.
Transposagen’s platform technologies have the advantages of having existing patent protection and the freedom to operate with no dominating intellectual property. The company has exclusive worldwide rights to several core technologies and over a dozen patents developed in-house and covering many product lines and human therapeutics.
Previous Investments & Opportunities
Transposagen has recently completed a $1.3 Million Series A investment. For information on investment opportunities please contact email@example.com.